Searchable abstracts of presentations at key conferences in endocrinology

ea0073aep346 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Use and effectiveness of dapagliflozin in type 1 diabetes: Clinical experience data of six months

José Ignacio Martínez Montoro , Andrea Fernández Valero , Fuentes Miguel Damas , José Luis Pinzón Martín , Tinahones Francisco J

IntroductionSodium-glucose cotransporter-2 inhibitors (SGLT2i) are a new class of oral antidiabetic drugs used for the treatment of type 2 diabetes mellitus. Recently, the SGLT2i dapagliflozin was approved for use in type 1 diabetes (T1DM) as an add-on to insulin therapy.Material and methodsWe conducted a retrospective observational study which included demographic and clinical-analytical data from 16 patient...

ea0073aep293 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Effectiveness of semaglutide in obese patients with type 2 diabetes. a six-month clinical experience

Andrea Fernández Valero , José Ignacio Martínez Montoro , Ana María Gómez Pérez , Damas-Fuentes Miguel , Francisco José Tinahones Madueño

IntroductionSemaglutide is a glucagon-like peptide-1 receptor agonist which has shown important benefits in patients with type 2 diabetes mellitus (T2DM) in randomized clinical trials. Its commercialization in Spain began in May of 2019. The main purpose of this study was to analyze the effectiveness of this drug into routine clinical practice in patients with T2DM with a body-mass index above 30 kg/m2.Matherial and meth...